close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Loratadine OTC status prompts care plans to revising non-sedating antihistamine coverage strategies

Loratadine OTC status prompts care plans to revising non-sedating antihistamine coverage strategies

YARDLEY, PA., Feb. 5, 2003 -- With Claritin joining the over-the-counter ranks, many health plans are in the process of revamping their prescription drug formularies.

The FDA announced OTC status approval for loratadine in November 2002. The status change had been requested by Schering-Plough in March after Wellpoint Health Networks filed a petition to switch Claritin, Allegra (fenofexadine) and Zyrtec (cetirizine) from prescription to OTC status.

Schering-Plough initially opposed the idea of switching Claritin to non-prescription status, but ultimately filed a supplemental new drug application to sell loratadine over-the-counter, itself.

MediMedia Information Technologies asked P&T committee members registered on PharmScope (pharmscope.com) for their input regarding changes to their formulary due to the over-the-counter status of loratadine and its effect on the non-sedating antihistamine class as a whole.    

This brief survey addresses the status of NSAs on formulary, costs to the plan and the likelihood of implementing policies that would encourage the use of Claritin OTC.

Results from the survey include:

  • Sixty-two percent of the respondents say a drug utilization/evaluation review is initiated for the drug class when a drug goes over-the-counter.
  • 59% of the plans will be moving desloratadine to a different, and, in most cases, lower status than loratadine.
  • Sixty-two percent do not expect NSAs to maintain their status.
  • Aetna will apply pre-certification to all prescription non-sedating antihistamines as of January 1, 2003.

To learn more about this survey, visit www.mminfotech.com.

Source:  MediMedia  Information Technologies

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
July 14, 2008
Audience: Oncologists, other healthcare professionals[Posted 07/14/2008] Genentech, Inc. informed healthcare professionals of...
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...